Opendata, web and dolomites

LOUISA-3D

Clinical validation of Laser Optoacoustic Ultrasonic 3D Imaging System Assembly for breast cancer detection and characterization through endogenous biomarkers.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 LOUISA-3D project word cloud

Explore the words cloud of the LOUISA-3D project. It provides you a very rough idea of what is the project "LOUISA-3D" about.

complete    board    breast    radiation    enhanced    commercializes    feasibility    scientific    clinical    affordable    functional    validated    commercialization    opportunity    imaging    introducing    capability    recall    bcs    predictive    view    validate    modality    marked    medical    hemoglobin    anatomical    full    detection    market    biomarkers    optoacoustic    population    once    enter    locally    therapy    device    commercialized    neoadjuvant    laser    oxygen    resonance    trial    international    release    protocols    validating    saturation    rate    limitations    effect    measuring    tomography    mammography    trials    images    first    plan    committee    standard    cancer    overcome    screening    company    coregistered    assembly    exogenous    endogenous    bios    nat    evaluation    representing    media    diagnostic    manufactured    contrast    deaths    ce    combines    resolution    ultrasound    characterization    positive    bc    treatment    women    blood    ionizing    sensitivity    louisa    digital    worldwide    ultrasonic    financial    risk    content    safe    3d    business    female    magnetic   

Project "LOUISA-3D" data sheet

The following table provides information about the project.

Coordinator
BIOS S.R.L. 

Organization address
address: VIA GUIDO ROSSA, 10/12
city: VIMODROME
postcode: 20090
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website https://ec.europa.eu/easme/en/sme/5478/clinical-validation-laser-optoacoustic-ultrasonic-3d-imaging-system-assembly-breast-cancer
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIOS S.R.L. IT (VIMODROME) coordinator 50˙000.00

Map

 Project objective

Breast cancer (BC) is the most common cancer and the first cause of cancer-related deaths in European women. Laser Optoacoustic Ultrasonic 3D Imaging System Assembly (LOUISA-3D) combines optoacoustic functional information from endogenous biomarkers (hemoglobin content and blood oxygen saturation) with high-resolution anatomical images of ultrasound tomography, without the need for ionizing radiation or exogenous contrast media. The objective of LOUISA-3D is to overcome the main limitations of current imaging methods, by validating and introducing to the EU market a novel multi-modality diagnostic device for BC, based on coregistered full view 3D optoacoustic and ultrasonic technology. LOUISA-3D will be a highly effective, safe and affordable imaging method for BC detection, characterization, and evaluation of the effect of neoadjuvant therapy (NAT). Two clinical trials will validate LOUISA-3D. Trial 1 will measure detection rate, recall rate, sensitivity, and positive predictive value of LOUISA-3D as a screening test in a selected female population at increased risk for BC, as compared to standard digital mammography. Trial 2 will assess the LOUISA-3D endogenous biomarkers capability of measuring the NAT effect in the treatment of locally advanced BCs, as compared to contrast-enhanced magnetic resonance imaging. During this feasibility study, an international scientific committee will deliver both trial protocols, and a management board will release a work and financial plan for the trials and a business plan for the production and commercialization of LOUISA-3D, complete market analysis, cost analysis and financial plan. The applying company, Bios, commercializes medical laser systems worldwide. Once validated and CE medical marked, LOUISA-3D will be manufactured and commercialized in EU, representing an important opportunity for Bios to enter the medical imaging market and enable its significant growth.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LOUISA-3D" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LOUISA-3D" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More